바이오톡스텍 086040

http://comp.fnguide.com/SVO2/asp/SVD_Main.asp?pGB=1&gicode=A086040&cID=&MenuYn=Y&ReportGB=&NewMenuID=101&stkGb=701

바이오톡스텍(A086040) | Snapshot | 기업정보 | Company Guide

- 2대 주주 셀트리온, 내년 상반가 코로나19 백신 위탁생산 추진 소식에
 상한가 16,050원 (+29.96%) - 2020.11.19
  ▷전일 언론에 따르면, 셀트리온이 국내 코로나19 백신 공급을 위해 내년 상반기 글로벌 
  제약사와 코로나19 백신 의약품 위탁생산(CMO)을 추진한다는 소식이 전해짐. 
  서정진 셀트리온 회장은 "세계적으로 100개 정도의 회사가 코로나19 백신을 개발하고 있는데, 
  내년 상반기에 10개 이상이 개발에 성공할 것이라 본다"며, "그 중에서 셀트리온이 위탁 
  생산할 수 있는 대상 회사가 있다면 같이 협업할 것"이라고 언급.
  ▷이 같은 소식에 셀트리온이 동사의 2대주주인 점이 시장에서 부각.
- 양호한 실적 + 하반기 정책 모멘텀 기대감 투자의견 목표주가 BUY 30,000원 
  현재가 (5/31) 15,150원 - KTB투자 - 2018.06.04
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=480022
- 화평법의 수혜 Not Rated 현재주가(5/17) 16,150원 - 현대차투자 - 2018.05.21 
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=478283
- 구조적 성장 사이클의 초입 투자의견 BUY 신규 목표주가 30,000 현재가 (5/4) 20,000원 -
  KTB투자 - 2018.05.08
  http://hkconsensus.hankyung.com/apps.analysis/analysis.downpdf?report_idx=475944